Four gene-therapy clinical trials starting in 2020 will make use of improved delivery ... the safety and long-term efficacy of AAV vector-mediated gene therapies, including navigating problems ...

Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...

There has been an increasing number of successful gene therapy clinical trials, leading to regulatory approvals of numerous gene therapy products, in particular ones based on the adeno-associated ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low ... paired with the capability to make billions of in vivo sequence-function ...

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

The client wanted to quickly determine whether their AAV vector could transduce RPE cells and whether transduction effectiveness was dose-dependent. Taking all project-specific aspects into ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...